Ingrid Herr

12.6k total citations · 3 hit papers
139 papers, 10.2k citations indexed

About

Ingrid Herr is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ingrid Herr has authored 139 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Biology, 42 papers in Oncology and 42 papers in Cancer Research. Recurrent topics in Ingrid Herr's work include Cell death mechanisms and regulation (28 papers), Cancer Cells and Metastasis (22 papers) and Genomics, phytochemicals, and oxidative stress (20 papers). Ingrid Herr is often cited by papers focused on Cell death mechanisms and regulation (28 papers), Cancer Cells and Metastasis (22 papers) and Genomics, phytochemicals, and oxidative stress (20 papers). Ingrid Herr collaborates with scholars based in Germany, United States and China. Ingrid Herr's co-authors include Klaus‐Michael Debatin, Claudia Friesen, Markus W. Büchler, Peter H. Krammer, Peter Angel, Jury Gladkich, Irmela Jeremias, Anja Apel, Hans van Dam and Gerhard Moldenhauer and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Neuroscience.

In The Last Decade

Ingrid Herr

138 papers receiving 10.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1996 868 citations Claudia Friesen, Ingrid Herr et al. profile →
Cellular stress response and apoptosis in cancer therapy

2001 668 citations Ingrid Herr, Klaus‐Michael Debatin Blood profile →
ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents.

1995 551 citations Ingrid Herr et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ingrid Herr	6.6k	3.0k	2.1k	1.8k	1.1k	139	10.2k
Curt Milliman	9.6k 1.4×	2.8k 0.9×	1.5k 0.7×	2.4k 1.3×	1.1k 1.0×	9	14.1k
Vinay Tergaonkar	6.4k 1.0×	1.9k 0.6×	3.3k 1.5×	2.5k 1.4×	887 0.8×	122	10.5k
Lawrence M. Pfeffer	5.4k 0.8×	3.2k 1.1×	3.1k 1.5×	3.6k 2.0×	901 0.8×	193	10.7k
Jinming Yang	4.7k 0.7×	2.5k 0.8×	2.1k 1.0×	1.3k 0.7×	1.2k 1.1×	190	7.8k
Paul J. Chiao	7.1k 1.1×	3.7k 1.2×	4.0k 1.9×	2.0k 1.1×	904 0.8×	135	11.2k
Nicholas Mitsiades	10.1k 1.5×	4.5k 1.5×	2.4k 1.1×	1.9k 1.1×	1.1k 1.0×	172	15.3k
Andreas Villunger	7.5k 1.1×	3.1k 1.0×	1.4k 0.7×	2.8k 1.6×	1.0k 0.9×	183	10.7k
Patrick Auberger	6.5k 1.0×	2.1k 0.7×	2.1k 1.0×	1.9k 1.0×	1.6k 1.5×	193	10.5k
Jerry E. Chipuk	9.1k 1.4×	2.6k 0.9×	1.5k 0.7×	1.8k 1.0×	1.6k 1.5×	89	12.4k
Senji Shirasawa	5.8k 0.9×	2.7k 0.9×	2.0k 0.9×	920 0.5×	626 0.6×	191	9.3k

Countries citing papers authored by Ingrid Herr

Since Specialization

Citations

This map shows the geographic impact of Ingrid Herr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Herr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Herr more than expected).

Fields of papers citing papers by Ingrid Herr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Herr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Herr. The network helps show where Ingrid Herr may publish in the future.

Co-authorship network of co-authors of Ingrid Herr

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Herr. A scholar is included among the top collaborators of Ingrid Herr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Herr. Ingrid Herr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Dan, et al.. (2025). Baicalein disrupts TGF-β-induced EMT in pancreatic cancer by FTO-dependent m6A demethylation of ZEB1. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1872(5). 119969–119969.

Sun, Yifeng, Yina Qiao, Yanan Niu, et al.. (2024). ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma. International Journal of Cancer. 156(6). 1272–1281. 1 indexed citations

Nickel, Felix, et al.. (2022). Toward 3D-bioprinting of an endocrine pancreas: A building-block concept for bioartificial insulin-secreting tissue. Journal of Tissue Engineering. 13. 1768581337–1768581337. 27 indexed citations

Liu, Li, Shanshan Han, Xi Xiao, et al.. (2022). Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy. Cell Death and Disease. 13(12). 1052–1052. 21 indexed citations

Yin, Libo, Jury Gladkich, Xi Xiao, et al.. (2019). Inhibition of miR30a-3p by sulforaphane enhances gap junction intercellular communication in pancreatic cancer. Cancer Letters. 469. 238–245. 36 indexed citations

Hage, Carina, Vanessa Rausch, Nathalia A. Giese, et al.. (2013). The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death and Disease. 4(5). e627–e627. 101 indexed citations

Salnikov, Alexei V., Jury Gladkich, Li Liu, et al.. (2012). New Gene-Immunotherapy Combining TRAIL-Lymphocytes and EpCAMxCD3 Bispecific Antibody for Tumor Targeting. Clinical Cancer Research. 18(4). 1028–1038. 16 indexed citations

Herr, Ingrid, Vladimir J. Lozanovski, Philipp Houben, Peter Schemmer, & Markus W. Büchler. (2012). Sulforaphane and related mustard oils in focus of cancer prevention and therapy. Wiener Medizinische Wochenschrift. 163(3-4). 80–88. 26 indexed citations

Rausch, Vanessa, Li Liu, Georgios Kallifatidis, et al.. (2010). Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics. Cancer Research. 70(12). 5004–5013. 169 indexed citations

10.

Salnikov, Alexei V., Anja Apel, Georgios Kallifatidis, et al.. (2009). Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. Journal of Cellular and Molecular Medicine. 13(9b). 4023–4033. 37 indexed citations

11.

Apel, Anja, Ingrid Herr, Heinz Schwarz, H. Peter Rodemann, & Andreas Mayer. (2008). Blocked Autophagy Sensitizes Resistant Carcinoma Cells to Radiation Therapy. Cancer Research. 68(5). 1485–1494. 442 indexed citations

12.

Büchler, Peter, Roman Ludwig, Nathalia A. Giese, et al.. (2007). PKC 412 small‐molecule tyrosine kinase inhibitor. Cancer. 110(7). 1457–1468. 21 indexed citations

13.

Herr, Ingrid, et al.. (2007). Adult stem cells in progression and therapy of hepatocellular carcinoma. International Journal of Cancer. 121(9). 1875–1882. 5 indexed citations

14.

Zhang, Chengwen, Alexander Marmé, Till Wenger, et al.. (2006). Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. International Journal of Oncology. 28(2). 551–8. 39 indexed citations

15.

Zhang, Chengwen, Benjamin M. Beckermann, Georgios Kallifatidis, et al.. (2006). Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. International Journal of Oncology. 29(5). 1295–301. 73 indexed citations

16.

Mattern, J, Axel Haferkamp, Jesco Pfitzenmaier, et al.. (2006). Corticosteriod-induced chemotherapy resistance in urological cancers. Cancer Biology & Therapy. 5(1). 59–64. 37 indexed citations

17.

Herzer, Kerstin, et al.. (2003). Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. International Journal of Cancer. 108(4). 580–587. 28 indexed citations

18.

Baumann, Bernd, Frank Bohnenstengel, Daniela Siegmund, et al.. (2002). Rocaglamide Derivatives Are Potent Inhibitors of NF-κB Activation in T-cells. Journal of Biological Chemistry. 277(47). 44791–44800. 73 indexed citations

19.

Posovszky, Carsten, Simone Fulda, Éric Meyer, et al.. (1999). Defective CD95-induced apoptosis in children with autoimmune lymphoproliferative syndrome (ALPS)/Canale-Smith-Syndrome (CSS) in the absence of CD95 mutations.. Blood. 94(10). 2 indexed citations

20.

Debatin, Klaus‐Michael, Claudia Friesen, Ingrid Herr, & Marek Łoś. (1996). Activation of the CD95 pathway by anticancer drugs.. Blood. 88(10). 2641–2641. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact